SindelkaG, HeinemannL, BergerM, et al.: Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia, 1994; 37:377–380.
GinH, Hanaire-BroutinH: Reproducibility and variability in the action of injected insulin. Diabetes Metab, 2005; 31:7–13.
4.
HomePD: The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab, 2012; 14:780–788.
5.
SøeborgT, RasmussenCH, MosekildeE, Colding-JørgensonM: Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci, 2009; 36:78–90.
6.
HeiseT, PieberTR, DanneT, et al.: Faster onset and greater early exposure and glucose-lowering effect with faster-acting insulin aspart vs. insulin aspart: a pooled analysis in subjects with type 1 diabetes. Diabetes, 2016; 65suppl 1:929P.
7.
BrangeJ, RibelU, HansenJF, et al.: Monmeric insulins obtained by protein engineering and their medical implications. Nature, 1988; 333:679–682.
8.
HansenJF. The self-association of zinc-free human insulin and insulin analogue B13-glutamine. Biophys Chem, 1991; 39:107–110.
9.
WoodworthJ, HoweyD, BowsherR, et al.: [Lys(B28), Pro(B29)] Human insulin (K): dose-ranging vs. humulin R (H). Diabetes, 1993; 42suppl 1:170.
10.
NosekL, RoggenK, HeinemannL, et al.: Diabetes, insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Obes Metab, 2013; 15:77–83.
11.
HeinemannL, WoodworthJ: Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today, 1998; 34:23–36.
12.
KakuK, MatsudaM, UraeA, IrieS: Pharmacokinetics and pharmaco-dynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract, 2000; 49:119–126.
13.
Gagnon-AugerM, Du SouichP, BaillargeonJ-P, et al.: Dose-dependant delay of the hypoglycemic effects of short-acting insulin analogs in obese subjects with type 2 diabetes. Diabetes Care, 2010; 33:2502–2507.
14.
PlankJ, BodenlenzM, SinnerF, et al.: A double-blind randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care, 2005; 28:1107–1112.
15.
BolliGB, HahnAD, SchmidtR, et al.: Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care, 2012; 35:2026–2630.
16.
LucidiP, PorcellatiF, CandeloroP, et al.: Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study. Nutr Metab Cardiovasc Dis, 2014; 24:709–716.
17.
GallowayJA, SpradlinCT, NelsonRL, et al.: Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care, 1981; 4:366–376.
18.
de la PeñaA, RiddleM, MorrowLA, et al.: Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care, 2011; 34:2496–2501.
19.
de la PeñaA, MaX, ReddyS, et al.: Application of PD/PK modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol, 2014; 8:821–829.
20.
BeckerRHA, DahmenR, BergmannK, et al.: New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care, 2005; 38:637–643.
21.
KorsatkoS, DellerS, KoehlerG, et al.: A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U.mL formulations of ultra-long_acting insulin degludec. Clin Drug Investig, 2013; 33:515–521.
22.
SeestedT, BurgessA, PykeC, et al.: Ultrastructural 3D visualization of insulin degludec multihexamers upon subcutaneous injection in pig. Diabetes, 2016; 65suppl 1:918P.
23.
HaahrH, HeiseT: A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet, 2014; 53:787–800.
24.
EbyEL, ZagarA, WangP, et al.: Healthcare costs and adherence associated with humulin regular U-500 versus high-dose U-100 insulin in patients with diabetes. Endocr Pract, 2014; 20:663–670.
25.
de la PeñaA, SegerM, SoonD, et al.: Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev, 2016; 5:69–75.
26.
MeadeLT, TartRC, NuzumD: Clinical experience with U-500 regular insulin by multiple daily injections and continuous subcutaneous insulin infusion. Diabetes Technol Ther, 2017; 19:220–225.
27.
EbyEL, WangP, CurtisBH, et al.: Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ, 2013; 16:529–538.
28.
EbyEL, CurtisBH, GelwicksSC, et al.: Initiation of human regular U-500 insulin use is associated with improved glycaemic control: a naturalistic US cohort study. BMJ Open Diabetes Res Care, 2015; 3:e000074.
29.
HoodRC, ArakakiFR, WyshamC, et al.: Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U 100 insulin with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract, 2015; 21:782–793.
30.
WyshamC, HoodRC, WarrenML, et al.: Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U 500 insulin in severely insulin-resistant patients with type 2 diabetes. Endocr Pract, 2016; 22:653–665.
31.
KabulS, HoodRC, DuanR, et al.: Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Health Qual Life Outcomes, 2016; 14:139–147.
32.
CSII vs TID MDI Lilly registration trial. clinicaltrials.gov NCT02561078 in progress. https://clinicaltrials.gov/ct2/show/NCT02561078?term=NCT02561078&rank=1 (accessed April3, 2017).
33.
Van BruntK, RooneyJ, CorriganSM: Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: a cross-sectional survey study. Diabetes Res Clin Pract, 2017; 126:30–42.
